- Home
- LUCD vs ACHV Comparison
LUCD vs ACHV Comparison
Compare LUCD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | ACHV |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 172.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LUCD | ACHV |
|---|---|---|
| Price | $1.02 | $4.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.13 | ★ $14.67 |
| AVG Volume (30 Days) | 901.2K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | N/A |
| Revenue Next Year | $130.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.90 | $2.00 |
| 52 Week High | $1.70 | $6.15 |
Technical Indicators
Market Signals| Indicator | LUCD | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 49.12 |
| Support Level | N/A | $4.04 |
| Resistance Level | $1.12 | $4.98 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 50.00 | 16.89 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.